Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...
You must submit your abstract using the online submission form. Abstracts sent by email will not be considered. Abstracts that are incomplete will not be considered. All ESA Annual Meeting proposal ...
Contributions on the topics listed in the Conference Announcement under Section C are welcome as oral or poster presentations. All submissions, apart from invited papers, must present original work, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback